Drug Development Pipeline
Acebilustat (CTX-4430) is an oral anti-inflammatory drug that reduces production of leukotriene B4 (LTB4), a molecule that leads to inflammation and is known to be elevated in people with CF. Reduction of inflammation helps prevent permanent tissue damage in the lungs.
A phase 2 study of Acebilustat did not meet its primary endpoint. No further development in CF is planned.
This program was sponsored by Celtaxsys and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Acebilustat (CTX-4430) Studies
Completed with Results
Phase 2 study of CTX-4430 in people with CF (EMPIRE) (Celtaxsys CTX-4430)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More